Biomarkers in Acute Cardiac Disease. The Present and the Future

Allan S Jaffe, Luciano Babuin, Fred S. Apple

Research output: Contribution to journalArticle

435 Citations (Scopus)

Abstract

The use of biomarkers to aid diagnosis and treatment is increasing rapidly as genomics and proteomics help us expand the number of markers we can use and as an improved understanding of the pathophysiology of cardiac disease guides their use. However, as with all rapidly expanding fields, there is the risk of excessive enthusiasm unless we are circumspect about the data that guide the clinical use of these new tools. This review focuses first on how to use troponin, which at present is the best validated of the new markers, and will hopefully provide insight into how to use this biomarker more productively by distinguishing subsets of patients and by providing an understanding of the meaning of elevations in various clinical situations. The review then discusses the use as well as the knowledge gaps associated with emerging biomarkers such as B-type natriuretic peptide and C-reactive protein, which are increasingly moving toward more productive clinical use. Finally, it reflects on some of the large number of markers that are still in development.

Original languageEnglish (US)
Pages (from-to)1-11
Number of pages11
JournalJournal of the American College of Cardiology
Volume48
Issue number1
DOIs
StatePublished - Jul 4 2006

Fingerprint

Acute Disease
Heart Diseases
Biomarkers
Troponin
Brain Natriuretic Peptide
Genomics
C-Reactive Protein
Proteomics
Therapeutics

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Biomarkers in Acute Cardiac Disease. The Present and the Future. / Jaffe, Allan S; Babuin, Luciano; Apple, Fred S.

In: Journal of the American College of Cardiology, Vol. 48, No. 1, 04.07.2006, p. 1-11.

Research output: Contribution to journalArticle

@article{19bbba4921304015b386ef0d63fe099c,
title = "Biomarkers in Acute Cardiac Disease. The Present and the Future",
abstract = "The use of biomarkers to aid diagnosis and treatment is increasing rapidly as genomics and proteomics help us expand the number of markers we can use and as an improved understanding of the pathophysiology of cardiac disease guides their use. However, as with all rapidly expanding fields, there is the risk of excessive enthusiasm unless we are circumspect about the data that guide the clinical use of these new tools. This review focuses first on how to use troponin, which at present is the best validated of the new markers, and will hopefully provide insight into how to use this biomarker more productively by distinguishing subsets of patients and by providing an understanding of the meaning of elevations in various clinical situations. The review then discusses the use as well as the knowledge gaps associated with emerging biomarkers such as B-type natriuretic peptide and C-reactive protein, which are increasingly moving toward more productive clinical use. Finally, it reflects on some of the large number of markers that are still in development.",
author = "Jaffe, {Allan S} and Luciano Babuin and Apple, {Fred S.}",
year = "2006",
month = "7",
day = "4",
doi = "10.1016/j.jacc.2006.02.056",
language = "English (US)",
volume = "48",
pages = "1--11",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - Biomarkers in Acute Cardiac Disease. The Present and the Future

AU - Jaffe, Allan S

AU - Babuin, Luciano

AU - Apple, Fred S.

PY - 2006/7/4

Y1 - 2006/7/4

N2 - The use of biomarkers to aid diagnosis and treatment is increasing rapidly as genomics and proteomics help us expand the number of markers we can use and as an improved understanding of the pathophysiology of cardiac disease guides their use. However, as with all rapidly expanding fields, there is the risk of excessive enthusiasm unless we are circumspect about the data that guide the clinical use of these new tools. This review focuses first on how to use troponin, which at present is the best validated of the new markers, and will hopefully provide insight into how to use this biomarker more productively by distinguishing subsets of patients and by providing an understanding of the meaning of elevations in various clinical situations. The review then discusses the use as well as the knowledge gaps associated with emerging biomarkers such as B-type natriuretic peptide and C-reactive protein, which are increasingly moving toward more productive clinical use. Finally, it reflects on some of the large number of markers that are still in development.

AB - The use of biomarkers to aid diagnosis and treatment is increasing rapidly as genomics and proteomics help us expand the number of markers we can use and as an improved understanding of the pathophysiology of cardiac disease guides their use. However, as with all rapidly expanding fields, there is the risk of excessive enthusiasm unless we are circumspect about the data that guide the clinical use of these new tools. This review focuses first on how to use troponin, which at present is the best validated of the new markers, and will hopefully provide insight into how to use this biomarker more productively by distinguishing subsets of patients and by providing an understanding of the meaning of elevations in various clinical situations. The review then discusses the use as well as the knowledge gaps associated with emerging biomarkers such as B-type natriuretic peptide and C-reactive protein, which are increasingly moving toward more productive clinical use. Finally, it reflects on some of the large number of markers that are still in development.

UR - http://www.scopus.com/inward/record.url?scp=33746405265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746405265&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2006.02.056

DO - 10.1016/j.jacc.2006.02.056

M3 - Article

C2 - 16814641

AN - SCOPUS:33746405265

VL - 48

SP - 1

EP - 11

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 1

ER -